Newsstand | Page 9 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Advances in antiviral drug cuts infection post SCT

Originally Published: 02/23/2017
  In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has shown that a novel agent can protect against the most common viral infection that patients face after transplantation. The results represent a breakthrough in a decade-long effort to identify an effective drug for the prevention of CMV infection in transplant patients that doesn’t produce side effects that negate the benefit of the drug itself, the study authors said. The findings, from an...

Foundation Update - February 2017

Originally Published: 02/17/2017
Foundation Update Newsletter - February 2017   MDS and Inflammation Dr. Alan List is the president and CEO of Moffitt Cancer Center in Tampa, Florida. He is a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. Prior to joining Moffitt in 2003, Dr. List was a professor of medicine and director of the Leukemia and Bone Marrow Transplant Program at the University of Arizona Tucson, as well as director of the Division of Translational/Clinical Research. Read Dr. List's comments on recent discoveries in inflammation as it...

Discovered: Simple way to identify GVHD risks

Originally Published: 02/09/2017
(New York, NY - February 3, 2017) --Researchers at Mount Sinai Health System have discovered a way to predict whether blood cancer patients who received a bone marrow transplant will develop graft-versus-host disease, a common and often lethal complication, according to a study published in JCI (The Journal of Clinical Investigation) Insight. This international study at 11 cancer centers examined blood samples from almost 1,300 bone marrow transplant patients and found that two proteins present in blood drawn a week after a transplant can predict whether a patient will develop a lethal...

New study hails test to weigh SCT for MDS

Originally Published: 02/09/2017
Newswise — A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research by scientists at Dana-Farber Cancer Institute and Brigham and Women’s Hospital. In a study published in the New England Journal of Medicine, the investigators report that genetically profiling a patient’s blood cells, while factoring in a patient’s age...

Strong results for SAA patients at Johns Hopkins

Originally Published: 02/07/2017
Physicians at the Johns Hopkins Kimmel Cancer Center report they have successfully treated 16 patients with a rare and lethal form of bone marrow failure called severe aplastic anemia using partially matched bone marrow transplants followed by two high doses of a common chemotherapy drug. In a report on the new transplant-chemo regimen, published online Dec. 22, 2016, in Biology of Blood and Marrow Transplantation, the Johns Hopkins team says that more than a year after their transplants, all of the patients have stopped taking immunosuppressive drugs commonly used to treat the disorder and...

Mayo Clinic links MDS with autoimmune drug

Originally Published: 02/03/2017
PHOENIX - Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. Researchers analyzed more than 40,000 patient cases with 27 common autoimmune diseases, such as Lupus, rheumatoid arthritis, among others, that were seen over a decade at Mayo Clinic. They identified 86 patients with therapy-related myeloid...

Medical “Must-See” TV in May

Originally Published: 02/02/2017
Near the nation’s capital, on the campus of the National Institutes of Health, sits Building 10: the largest hospital in the world devoted solely to research. Inside, our country’s most brilliant scientific minds carry out some of medicine’s riskiest and most critical research, testing new treatments in people for the very first time. With unprecedented access to the halls of Building 10, First in Human reveals for the first time how the medical breakthroughs of tomorrow make their way out of the hi-tech research laboratories and into the hands of our world’s medical professionals.  The...

MDS Update - February 2017

Originally Published: 02/01/2017
MDS Update - February 2017

MDS expert finds promising antibody

Originally Published: 01/25/2017
A protein-sugar molecule, CD99, occurs more frequently than normal on stem cells responsible for blood cancers, including acute myeloid leukemia (AML) and the related myelodysplastic syndromes (MDS). This is the finding of a study led by researchers from NYU Langone Medical Center and Memorial Sloan Kettering Cancer Center, and published online Jan. 25 in Science Translational Medicine. Building on this discovery, the study authors designed an antibody that recognizes and destroys CD99-covered leukemia cells while sparing normal blood stem cells, a finding confirmed by experiments in human...

Foundation Update - January 2017

Originally Published: 01/19/2017
Foundation Update Newsletter - January 2017   How Does Bone Marrow Failure Disease Affect Pregnancy? Dr. Ellen Friedman has been the Hematology Fellowship Director of Montefiore Medical Center/Albert Einstein College of Medicine since 2005. She completed a fellowship in hematology at New York University, specializing in the conditions of red cells, platelets and hematologic malignancies. Her research has focused on a variety of blood conditions including anemia, thrombocytopenia, and myelodysplastic syndrome. Read Dr. Friedman's remarks about pregnancy and bone...